Zusammenfassung
Sobald eine raumfordernde Läsion in der Schädelhöhle akut ein Volumen von mehr als 50 ml erreicht, wirkt sie komprimierend auf das Hirngewebe und kann zu Funktionsstörungen, z. B. zu einer Lähmung führen. Wenn sie weiter an Volumen zunimmt und lebenswichtige Hirnanteile komprimiert werden, geben diese ihre Funktion auf, der Patient wird bewusstlos und kann an der raumfordernden Läsion sterben. Auch die Geschwindigkeit, mit der sich die raumfordernde Läsion entwickelt, spielt eine Rolle. Beim Erwachsenen kann die starre Schädelkapsel der Volumenvermehrung durch die intrakranielle Geschwulst nicht nachgeben. Die Hüllstrukturen (Dura, Knochen) lassen keine wesentlichen Ausweichmöglichkeiten für einen raumfordernden Prozess zu. Dies gilt nicht für Tumoren im frühen Kindesalter, wenn die Knochennähte und Fontanellen noch nicht geschlossen sind.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsWeiterführende Literatur
Bettegowda C, Agrawal N, Jiao Y, et al. (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453–1435
Brandsma D, Stalpers L, Taal W, et al. (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncology 9:453–461
Cairncross G, Wang M, Shaw E, et al. (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343
Chinot O, Wick W, Mason W, et al. (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722
Dolecek TA, Propp JM, Stroup NE, Kruchko C (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005–2009. Neuro-Oncology 14:Suppl 5:v1–49
Fogh SE, Andrews DW, Glass J, et al. (2010) Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol 28:3048–3053
Franz DN, Belousova E, Sparagana S, et al. (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomized, placebo-controlled phase III trial. Lancet 381:125–132
Gilbert MR, Dignam JJ, Won M, Armstrong TS, et al. (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708
Glantz MJ, Cole BF, Forsyth, PA, et al. (2000) Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54:1886–1893
Hartmann C, Hentschel B, Wick W, et al. (2010) Patients with IDH1 wild type anaplastic astroctytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718
Hegi ME, Diserens AC, Gorlia T, et al. (2005) MGMT gene silencing and response to temozolomide in glioblastoma. N Engl J Med 352:997–1003
Herrlinger U, Felsberg J, Küker W, et al. (2002Gliomatosis cerebri. Molecular pathology and clinical course. Ann Neurol 52:390–399
Jones DT, Hutter B, Jäger N, et al. (2013Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet 45:927–932
Krüger DA, Care MM, Holland K, et al. (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801–1811
Landolfi JC, Thaler HT, DeAngelis LM (1998) Adult brainstem gliomas. Neurology 51:1136–1139
Louis DN, Ohgaki H, Wiestler OD, et al. (2007) WHO classification of tumours of the central nervous system. IARC, Lyon
Malmström A, Grønberg BH, Marosi C, et al. (2012) Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy for patients aged over 60 years with glioblastoma: the Nordic randomized phase 3 trial. Lancet Oncol 13:916–926
Marras LC, Geerts WH, Perry JR (2000) The risk of venous thromboembolism is increased throughout the course of malignant glioma. Cancer 89:640–646
Pignatti F, van den Bent M, Curran D, et al. (2002Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084
Roth P, Wick W, Weller M (2010) Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol 23:597–602
Schindler G, Capper D, Meyer J, et al. (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121:397–405
Schwartzentruber J, Korshunov A, Liu XY, et al. (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482 226–231
Soffietti R, Baumert BG, Bello L, et al. (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO* Task Force. Eur J Neurol 17:1124–1133
Stummer W, Pichlmeier U, Meinel T, et al. (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401
Stummer W, Reulen HJ, Meinel T, et al. (2008Extent of resection and survival in glioblastoma multiforma: identification of and adjustment for bias. Neurosurgery 62:564–576
Stupp R, Mason WP, van den Bent MJ, et al. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for patients with newly diagnosed glioblastoma. N Engl J Med 352:987–996
Van den Bent M, Brandes AA, Taphoorn M, et al. (2013) Adjuvant procarbacine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. J Clin Oncol 31:344–350
Veeravagu A, Jiang B, Ludwig C, et al. (2013) Biopsy versus resection for the management of low-grade glioma. Cochrane Database of Systematic Reviews., Issue 5. Art. No.: CD009319
Weller M, Stupp R, Wick W (2012) Epilepsy meets cancer: when, why, and what to do about it? Lancet Oncol 13:e375–e382
Weller M, Pfister SM, Wick W, Hegi ME, Reifenberger G, Stupp R (2013) Molecular neuro-oncology entering clinical practice: a new horizon. Lancet Oncol 14:e370–e379
Wen PY, Macdonald DR, Reardon DA, et al. (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972
Westphal M, Hilt DC, Bortey E, et al. (2003A phase 3 trial of local chemotherapy with biodegradable wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncology 5:79–88
Westphal M, Ram Z, Riddle V, et al. (2006Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien) 148:269–375
Wick W, Hartmann C, Engel C, et al. (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. J Clin Oncol 27:5874–5880
Wick W, Platten M, Meisner C, et al., for the Neurooncology Working Group (NOA) of the German Cancer Society (2012) Chemotherapy versus radiotherapy for malignant astrocytoma in the elderly. Lancet Oncol 13:707–715
Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G (2014) MGMT testing in neurooncology – A paradigm for prospects and challenges of biomarker-based treatment decisions. Nat Rev Neurol 10:372–85
Yan H, Parsons DW, Jin G, et al. (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Wick, A., Unterberg, A., Debus, J. (2016). Hirntumoren. In: Hacke, W. (eds) Neurologie. Springer-Lehrbuch. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46892-0_11
Download citation
DOI: https://doi.org/10.1007/978-3-662-46892-0_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46891-3
Online ISBN: 978-3-662-46892-0
eBook Packages: Medicine (German Language)